The GLP-1 drug category — Ozempic, Wegovy, Mounjaro, and the compounds behind them — has produced one of the fastest market expansions in pharmaceutical history. The forecasts keep being revised upward because the forecasts keep underestimating demand.
Part of what makes this unusual is that the demand is coming from multiple directions simultaneously. There is the core obesity treatment indication, which alone represents a market of several hundred million people globally. There are emerging indications — cardiovascular outcomes, sleep apnea, kidney disease, addiction — that are expanding the addressable population beyond weight loss. And there is significant off-label and cash-pay demand from people who do not qualify under insurance criteria but are willing to pay out of pocket.
The supply constraint has been the binding factor for most of the past two years. Novo Nordisk and Eli Lilly have invested billions in manufacturing expansion, but peptide drug production is slow to scale and the build-out has lagged demand consistently. This created shortages, compounding pharmacies filling the gap with lower-cost alternatives, and a regulatory fight about whether those alternatives are permissible — all of which is still playing out.
The downstream effects are only beginning to register. Health insurers are wrestling with whether covering these drugs reduces long-term costs enough to justify the near-term expense. Employers are splitting on the question. Food and beverage companies are recalibrating volume projections if a meaningful portion of their market is pharmacologically appetite-suppressed. Bariatric surgery volumes are declining.
The drugs work. That is not usually how pharmaceutical stories go. When they do, the disruption tends to be larger and more durable than initial projections capture. We are in the early chapters of a long story.